SCHEMBL13825035

SCHEMBL13825035

CCOC(=O)c1cc(-c2ccccc2)cn2c(=O)[nH]nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.48
ALDH1A1 P00352 7/20 0.47
SMN1; SMN2 Q16637 7/20 0.47
KDM4E B2RXH2 6/20 0.47
HPGD P15428 5/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 5/20 0.46
GAA P10253 3/20 0.44
TSHR P16473 3/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
CSNK1D P48730 1/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13825028 0.82 LTK (0.48) ALDH1A1KDM4EPDE3BPDE3A
SCHEMBL13825030 0.80 LTK (0.46) ALDH1A1KDM4EHPGDCSNK1DPDE3B
SCHEMBL13824909 0.74 LTK (0.50) CSNK1DPDE3BPDE3A
SCHEMBL13825055 0.73 MEN1 (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDRAB9A
SCHEMBL25101266 0.71 KDM4E (0.43) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL13825031 0.70 GSK3A (0.50) ALDH1A1SMN1; SMN2KDM4EHPGDRAB9A
SCHEMBL4436705 0.70 KDM4E (0.55) HPGDSALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL14252251 0.70 TSHR (0.65) ALDH1A1SMN1; SMN2KDM4EHPGDRAB9A
SCHEMBL13824906 0.69 RET (0.42) ALDH1A1KDM4EHPGDRAB9ANPC1
SCHEMBL28757629 0.69 TSHR (0.58) ALDH1A1SMN1; SMN2KDM4EHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012150829-A2 NOBLE TRIAZOLOPYRIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME 제일약품주식회사 (KR) 2012-11-08 WO disclosed